Vector Evolution News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Vector Evolution. Real-time updates on events, politics, business and more.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

January 3, 2024

Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates...

United Kingdom United States Julian Pei David Walt Devyn Smith Katherine Smith

Source: marketscreener.com

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY)

July 11, 2023

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, &#34;Astellas&#34;) and 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) (CEO: David Kirn, MD,

David Kirn Naoki Okamura Adam Pearson Astellas Pharma Inc Prnewswire Astellas Pharma Inc D Molecular Therapeutics Inc

Source: benzinga.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Vector Evolution News Today

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY)

Explore More Categories